BIO-TECHNE Corp vs Wix.Com Ltd — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Wix.Com Ltd trades at $66.58 (market cap $2.61B). The key difference: BIO-TECHNE Corp is far larger — about 4.3× Wix.Com Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| TECH | WIX | |
|---|---|---|
Market Cap | $11.24B | $2.61B |
Sector | Health | Technology |
52-Week High | $72.29 | $184.24 |
52-Week Low | $43.31 | $40.43 |
Enterprise Value | $11.32B | $3.69B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Wix trades at $60.20, down 1.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75 suggesting significant upside. Revenue grew to $1.99 billion in 2025, though net income margin remains negative at -8.19%. Recent earnings show three beats and one miss in the last four quarters, with a notable 27% price drop following the Q1 2026 miss.
The outlook is mixed: strong revenue growth and analyst optimism contrast with profitability challenges and a securities class action lawsuit alleging misleading statements. The stock offers potential for appreciation if execution improves, but faces near-term legal and operational risks that could pressure the share price.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →